# Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)

Study · id `cardio:ct-nct02829151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02829151](<https://clinicaltrials.gov/study/NCT02829151>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02829151

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.

## Technical summary

Registry record NCT02829151. Randomized; no masking; primary purpose treatment. Start 2017-02-21 (actual); primary completion 2021-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 390 participants (planned count; ClinicalTrials.gov record NCT02829151, source copy `cardio:ctgov-nct02829151-2019-01-14`, retrieved 2026-10-31)
- Started: 2017-02-21 (actual) (ClinicalTrials.gov record NCT02829151, source copy `cardio:ctgov-nct02829151-2019-01-14`, retrieved 2026-10-31)
- Primary completion: 2021-10 (anticipated) (ClinicalTrials.gov record NCT02829151, source copy `cardio:ctgov-nct02829151-2019-01-14`, retrieved 2026-10-31)
- Completion: 2021-10 (anticipated) (ClinicalTrials.gov record NCT02829151, source copy `cardio:ctgov-nct02829151-2019-01-14`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT02829151, source copy `cardio:ctgov-nct02829151-2019-01-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02829151-2019-01-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)
- Condition: Critical Limb Ischemia
- Intervention (Drug): Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )
- Intervention (Drug): Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel
- Intervention (Drug): Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: f1f51786463d84947e135ae450e07498d5f1996edad69be22e36fdd864b1cefb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
